These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 625529)

  • 1. Neuroendocrine studies with dopamine agonists in schizophrenia.
    Rotrosen J; Angrist B; Paquin J
    Psychopharmacol Bull; 1978 Jan; 14(1):14-7. PubMed ID: 625529
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroendocrine assessment of dopaminergic activity in schizophrenia.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Adv Biochem Psychopharmacol; 1977; 16():649-53. PubMed ID: 883563
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM
    Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet monoamine oxidase and the growth hormone response to apomorphine in schizophrenia.
    Malas KL; van Kammen DP; deFraites EA; Brown GM; Gold PW
    Biol Psychiatry; 1983 Feb; 18(2):255-9. PubMed ID: 6830934
    [No Abstract]   [Full Text] [Related]  

  • 7. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNV and dopamine receptor reactivity: correlations with the apomorphine test.
    Timsit-Berthier M; Mantanus H; Marissiaux P; Ansseau M; Doumont A; Geenen V; Legros JJ
    Electroencephalogr Clin Neurophysiol Suppl; 1986; 38():403-5. PubMed ID: 3466779
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroendocrine function in schizophrenia.
    Brambilla F
    Acta Psychiatr Belg; 1980; 80(4):421-35. PubMed ID: 6792866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar response to dopaminergic or anti-dopaminergic drugs in acromegaly.
    Tater D; Maudelonde T; Sudre Y; Besson G; Bercovici JP
    Horm Metab Res; 1984 Feb; 16(2):104-5. PubMed ID: 6706287
    [No Abstract]   [Full Text] [Related]  

  • 12. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
    Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
    [No Abstract]   [Full Text] [Related]  

  • 13. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists induce recovery from surgically-induced septal rage.
    Marotta RF; Logan N; Potegal M; Glusman N; Gardner EL
    Nature; 1977 Oct; 269(5628):513-5. PubMed ID: 909599
    [No Abstract]   [Full Text] [Related]  

  • 16. [Significance of blood levels of prolactin and somatotropin as indices of pharmacological effects on the central nervous system].
    Barreca T; Gallamini A; Murialdo G; Nizzo MC; Polleri A
    Clin Ter; 1978 Jul; 86(2):147-59. PubMed ID: 743856
    [No Abstract]   [Full Text] [Related]  

  • 17. alpha and beta Dopamine receptors?
    Debono AG; Marsden CD; Parkes JD
    Acta Neurol Belg; 1976; 76(5-6):315-7. PubMed ID: 1007899
    [No Abstract]   [Full Text] [Related]  

  • 18. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
    Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion.
    Goodnick PJ; Meltzer HY
    J Clin Psychopharmacol; 1983 Aug; 3(4):239-43. PubMed ID: 6411776
    [No Abstract]   [Full Text] [Related]  

  • 20. [Controlled study of L-dopa in schizophrenia with reference to the theory of hypersensitivity of dopamine receptors].
    Beramendi V; Alpert M; Guimón J; Friedhoff A; Gutiérrez M
    Arch Neurobiol (Madr); 1980; 43(2):107-24. PubMed ID: 6996632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.